News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG (NVS) to Shut Down Brain Research Facility; Redirects Psychiatric Efforts to Genetics


12/7/2011 8:14:23 AM

Novartis has joined other pharmaceutical companies in abandoning traditional drug-discovery programmes that pursue treatments for brain disorders. Nature has learned that the company is closing its neuroscience facility in Basel, Switzer­land, where Novartis is headquartered. It follows similar moves by GlaxoSmithKline and AstraZeneca, both based in the United Kingdom, which last year announced the closure of all their neuroscience research divisions globally. US-based companies Pfizer and Merck, as well as the French company Sanofi, have also pulled back on research into brain disorders. Rather than abandon neuroscience, however, Novartis says it will launch new programmes to study the genetics of psychiatric and cognitive disorders, in the hope of identifying new treatment strategies.

Read at Nature
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES